Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 749 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded322    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

Year : 2005  |  Volume : 47  |  Issue : 2  |  Page : 102-105

Effectiveness of clozapine in treatment-resistant schizophrenia

1 Department of Psychiatry, Doncaster Royal Infirmary, Sheffield Care Trust, DN2 5LT, United Kingdom
2 Department of Psychiatry, Tirupati Medical College, Andhra Pradesh, India
3 Department of Psychiatry, JIPMER, Pondicherry 605006, India

Correspondence Address:
Janakiraman Raguraman
Department of Psychiatry, Doncaster Royal Infirmary, Sheffield Care Trust, DN2 5LT
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5545.55955

Rights and Permissions

Background: Clozapine has been shown to be superior to chlorpromazine in improving the positive and negative symptoms of schizophrenia. However, technical experience with clozapine in Indian patients has not been documented. Aim: To assess the improvement in psychopathology of treatment-resistant schizophrenia with clozapine therapy and to study the relationship between sociodemographic and various psychopathology variables among patients with treatment-resistant schizophrenia. Methods: Twenty-two patients with treatment-resistant schizophrenia were evaluated using the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Calgary Depression Scale, Global Assessment of Functioning (GAF) Scale and Abnormal Involuntary Movement Scale (AIMS). These scales were used to determine the level of psychopathology, depression, overall functioning and severity of abnormal involuntary movements in the patients. The patients were admitted to the hospital for a short time to initiate clozapine therapy. At discharge, patients were stabilized on 300-400 mg/day of clozapine. The patients were re­evaluated after 20 months. Results: The study group showed better global functioning after clozapine therapy. The therapy was well­tolerated though moderate side-effects were seen. Suicidal thoughts declined with clozapine therapy. There was a significant reduction in the negative symptom and general psychopathology scores of PANSS. Conclusion: Clozapine has therapeutic efficacy in some but not all treatment-resistant patients with schizophrenia.



Print this article         Email this article